Literature DB >> 16552076

Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen.

Jesse Wells1, Constantine G Haidaris, Terry W Wright, Francis Gigliotti.   

Abstract

Mice immunized with recombinant mouse Pneumocystis carinii antigen A12-thioredoxin fusion protein developed an antibody response that recognized P. carinii antigens, as determined by Western blotting and immunofluorescence analysis. Compared to mice immunized with thioredoxin alone, mice immunized with A12-thioredoxin had significantly reduced lung P. carinii burdens after CD4+ T-cell depletion and challenge with P. carinii.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16552076      PMCID： PMC1418926          DOI： 10.1128/IAI.74.4.2446-2448.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  14 in total

1.  Recombinant major surface glycoprotein of Pneumocystis carinii elicits a specific immune response but is not protective in immunosuppressed rats.

Authors:  M E Lasbury; C W Angus; D Klivington; P J Durant; M S Bartlett; J W Smith; C H Lee
Journal:  J Eukaryot Microbiol       Date:  1999 Sep-Oct       Impact factor: 3.346

2.  CD4+ T cell-independent DNA vaccination against opportunistic infections.

Authors:  Mingquan Zheng; Alistair J Ramsay; Myles B Robichaux; Corrine Kliment; Christopher Crowe; Rekha R Rapaka; Chad Steele; Florencia McAllister; Judd E Shellito; Luis Marrero; Paul Schwarzenberger; Qiu Zhong; Jay K Kolls
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

3.  CD4+ T cell-independent vaccination against Pneumocystis carinii in mice.

Authors:  M Zheng; J E Shellito; L Marrero; Q Zhong; S Julian; P Ye; V Wallace; P Schwarzenberger; J K Kolls
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: characterization of epitope recognition associated with immunization.

Authors:  A G Smulian; D W Sullivan; S A Theus
Journal:  Microbes Infect       Date:  2000-02       Impact factor: 2.700

5.  A Pneumocystis carinii multi-gene family with homology to subtilisin-like serine proteases.

Authors:  Elena B Lugli; Andrew G Allen; Ann E Wakefield
Journal:  Microbiology (Reading)       Date:  1997-07       Impact factor: 2.777

6.  Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia.

Authors:  Francis Gigliotti; Constantine G Haidaris; Terry W Wright; Allen G Harmsen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

7.  Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response.

Authors:  S A Theus; A G Smulian; P Steele; M J Linke; P D Walzer
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

8.  Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia.

Authors:  F Gigliotti; J A Wiley; A G Harmsen
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

9.  Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice.

Authors:  A G Harmsen; W Chen; F Gigliotti
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

10.  Intranasal immunization confers protection against murine Pneumocystis carinii lung infection.

Authors:  J M Pascale; M M Shaw; P J Durant; A A Amador; M S Bartlett; J W Smith; R L Gregory; G L McLaughlin
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441
View more
  26 in total

1.  Novel pneumocystis antigen discovery using fungal surface proteomics.

Authors:  Mingquan Zheng; Yang Cai; Taylor Eddens; David M Ricks; Jay K Kolls
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  Oral Immunization of Mice with Live Pneumocystis murina Protects against Pneumocystis Pneumonia.

Authors:  Derrick R Samuelson; Nicholas M de la Rua; Tysheena P Charles; Sanbao Ruan; Christopher M Taylor; Eugene E Blanchard; Meng Luo; Alistair J Ramsay; Judd E Shellito; David A Welsh
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

Review 3.  Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

4.  Pneumocystis workshop: 10th anniversary summary.

Authors:  James M Beck; Melanie T Cushion
Journal:  Eukaryot Cell       Date:  2009-01-23

5.  Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection.

Authors:  Heather M Kling; Timothy W Shipley; Siobhan Guyach; Rebecca Tarantelli; Alison Morris; Karen A Norris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

Review 6.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

7.  Pneumocystis infection and the pathogenesis of chronic obstructive pulmonary disease.

Authors:  Karen A Norris; Alison Morris
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

8.  Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.

Authors:  Matthew R Gingo; Lorrie Lucht; Kieran R Daly; Kpandja Djawe; Frank J Palella; Alison G Abraham; Jay H Bream; Mallory D Witt; Lawrence A Kingsley; Karen A Norris; Peter D Walzer; Alison Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

9.  The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus.

Authors:  R Buissa-Filho; R Puccia; A F Marques; F A Pinto; J E Muñoz; J D Nosanchuk; L R Travassos; C P Taborda
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

10.  Characterization of a novel ADAM protease expressed by Pneumocystis carinii.

Authors:  Cassie C Kennedy; Theodore J Kottom; Andrew H Limper
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.